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Objectives In this study, we evaluated the impact of 2 common 1-adrenergic receptor (1-AR) polymorphisms (G389R and
S49G) in response to ventricular rate control therapy in patients with atrial fibrillation (AF).
Background Randomized studies have shown that ventricular rate control is an acceptable treatment strategy in patients with AF.
However, identification of patients who will adequately respond to rate-control therapy remains a challenge.
Methods We studied 543 subjects (63% men; age 61.8  14 years) prospectively enrolled in the Vanderbilt AF registry and
managed with rate-control strategy. A “responder” displayed adequate ventricular rate control based on the AFFIRM
(Atrial Fibrillation Follow-Up Investigation of Rhythm Management) criteria: average heart rate (HR) at rest 80
beats/min; and maximum HR during a 6-min walk test 110 beats/min or average HR during 24-h Holter 100
beats/min.
Results A total of 295 (54.3%) patients met the AFFIRM criteria. Baseline clinical characteristics were similar in re-
sponders and nonresponders except for mean resting HR (76  20 beats/min vs. 70  15 beats/min; p 
0.01) and smoking (6% vs. 1%; p  0.01). Multiple clinical variables (age, gender, hypertension) failed to predict
response to rate-control therapy. By contrast, carriers of Gly variant at 389 were more likely to respond favorably
to rate-control therapy; 60% versus 51% in the Arg389Arg genotype, p  0.04. This association persisted after
correction for multiple clinical factors (odds ratio: 1.42, 95% confidence interval: 1.00 to 2.03, p  0.05).
Among responders, subjects carrying the Gly389 variant required the lowest doses of rate-control medications;
atenolol: 92 mg versus 68 mg; carvedilol: 44 mg versus 20 mg; metoprolol: 80 mg versus 72 mg; diltiazem:
212 mg versus 180 mg, and verapamil: 276 mg versus 200 mg, respectively (p  0.01 for all comparisons).
Conclusions We have identified a common 1-AR polymorphism, G389R, that is associated with adequate response to rate-
control therapy in AF patients. Gly389 is a loss-of-function variant; consequently, for the same adrenergic stimu-
lation, it produces reduced levels of adenyl cyclase, and hence, attenuates the -adrenergic cascade. Mechanisti-
cally, the effect of rate-control drugs will be synergistic with that of the Gly389 variant, which could possibly
explain our findings. These findings represent a step forward in the development of a long-term strategy of se-
lecting treatment options in AF based on genotype. (J Am Coll Cardiol 2012;59:49–56) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.061tAtrial fibrillation (AF) is the most common arrhythmia in
clinical practice in the United States today, affecting over 2
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accepted August 23, 2011.million people (1). A common target for pharmacological
therapies in cardiovascular diseases is the 1-adrenergic recep-
or (1-AR) ADRB1, and -blocking medications are con-
sidered first-line agents for ventricular rate control in patients
withAF (2,3). TheADRB1 is amember of the superfamily of cell
surface receptors that carry out signaling via coupling to guanine
See page 57
nucleotide binding proteins (G proteins), activated by cate-
cholamine binding, which increases intracellular cyclic-
adenosine monophosphate activity, resulting in increased
chronotropic and inotropic effects on the myocardium.
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onymous single nucleotide poly-
morphisms (SNPs) of the ADRB1
found in the humans. At position
49 in the amino-terminus of the
receptor, a serine is substituted by
a glycine (Ser49Gly) with an allele
frequency of 12% to 16% in Cau-
casians and Asians and 13% to
28% in African Americans (4,5).
At position 389 in the proximal
portion of the carboxy-terminus in
the cytoplasmic tail, an arginine
is substituted by a glycine
(Arg389Gly) with an allele fre-
quency of 24% to 34% in Cauca-
sians and Asians and 39% to 46%
in African Americans (5).
In vitro studies, which largely
have been conducted in mice or
rodent ventricular myocytes,
have demonstrated that both the Ser49Gly and Arg389Gly
NPs are functional; earlier studies showed that the Gly49
R expresses higher basal and agonist-stimulated adenylyl
yclase activity and increased agonist-promoted down-
egulation compared with the Ser49 variant, whereas the
rg389 allele has 3 times greater adenylyl cyclase activity in
esponse to agonist than the Gly389 variant (5,6). However,
ecent studies have reported that the effect on adenyl cyclase
ctivity is primarily due to allelic variants on position 389
nd not 49, which may only play a modulating role yet to be
ully determined (7). Studies have also assessed the effects of
hese SNPs on resting hemodynamics and incidence of
ypertension (HTN). Bengtsson et al. (8) in a study of
enotype-discordant siblings reported that siblings homozy-
ous for the Arg389 allele had significantly higher heart
ates (HRs) and diastolic blood pressure and were more
ikely to be hypertensive compared with siblings heterozy-
ous or homozygous for the Gly389 allele. However, several
other studies have met with mixed results (9,10).
Although the role of ADRB1 polymorphisms has been
xtensively investigated in HTN and heart failure, it is only
ecently that a study showed that the Arg389Gly polymor-
hism modulates responsiveness to -blockade in heart
ailure patients (11). However, the role of these common
DRB1 polymorphisms in modulating response to atrioven-
ricular (AV) nodal blocking drugs in AF patients has not been
etermined. Here, we tested the hypothesis that 2 common
NPs in the ADRB1 (Ser49Gly and Arg389Gly) modulate
response to rate-control therapy in patients with AF.
Methods
Study population. The study was performed in patients
prospectively enrolled in the Vanderbilt AF Registry, which
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
AR  adrenergic receptor
AV  atrioventricular
BB  -blocker
CCB  calcium channel
blocker
CHF  congestive heart
failure
CI  confidence interval
HR  heart rate
HTN  hypertension
LD  linkage disequilibrium
OR  odds ratio
SNP  single nucleotide
polymorphismis a clinical and a genetic registry (12). Inclusion criteria vinclude age 18 years, a documented history of AF or atrial
flutter, and attempted rate control using a -blocker,
calcium channel blocker, or digoxin. An echocardiogram
was obtained on all patients at the time of enrollment into
the registry. The treating physicians were blinded to the
study protocol and subsequent genotype data. Study inves-
tigators were not involved in patient management. Written
informed consent was obtained from all patients under a
protocol approved by the Vanderbilt University Institutional
Review Board.
Definitions. Arterial HTN was defined by a history of
HTN and/or the presence of antihypertensive therapy.
Criteria for coronary artery disease included a history of
myocardial infarction or typical angina, previous bypass
surgery or angioplasty, and drug treatment. Congestive
heart failure was defined by a history and/or drug treatment
for heart failure. Left atrial and left ventricular measure-
ments from the M-mode echocardiograms were made by an
experienced physician blinded to the genotype status of the
patient. The echocardiograms were evaluated according to
the recommendations of the American Society of Echocar-
diography. Drug prescription distribution was defined as the
total number of prescriptions written by the treating physi-
cians for both responders and nonresponders, including
alteration of dose of an already prescribed medication
and/or addition of a new medication to control AF. Family
history of AF was defined as electrocardiographically doc-
umented AF in 1 or more first-degree family members of
the study subject.
Response to rate-control therapy. Responders were pro-
spectively defined as patients who achieved adequate rate
control, meeting the AFFIRM (Atrial Fibrillation Follow-up
Investigation of Rhythm Management) study criteria: aver-
age HR 80 beats/min at rest and maximum HR 110
beats/min during a 6-min walk test or average HR during
24-h ambulatory Holter monitoring electrocardiogram
100 beats/min (at least 18 h of interpretable monitoring)
and no HR 110% maximum predicted age-adjusted ex-
ercise HR (13). Nonresponders were patients who failed to
meet the AFFIRM criteria necessitating addition of an
anti-arrhythmic drug (AAD) or nonpharmacological ther-
apies such as AV node ablation and pacemaker implantation
in 6 months from study entry.
Determination of 1-AR genotypes. ADRB1 genotyping
or the Arg389Gly and Ser49Gly variants was performed by
aboratory personnel who had no knowledge of the response
o rate-control therapy. Genomic deoxyribonucleic acid was
solated from whole blood by a commercial kit (Purgene;
entra Systems, Minneapolis, Minnesota). Genotyping was
erformed for rs1801252 CG (Ser49Gly) and rs1801253
T (Arg389Gly) using a TaqMan assay (Applied Biosys-
ems, Foster City, California) as previously described (14).
tatistical analysis. All data are expressed as mean  SD.
hi-square analysis or Fisher exact test was performed on
iscrete variables and Mann-Whitney U test on continuous
ariables. After applying quality control criteria to the
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December 27, 2011/January 3, 2012:49–56 Genetic Predictors of AF Rate-Control Therapygenotypic data, Hardy-Weinberg equilibrium was assessed.
Due to expected low numbers, homozygous variants (Gly49
and Gly389) were pooled with respective heterozygous
variants to formulate a cumulative group of carriers of minor
allele, which were defined a priori. Logistic regression with
dominant, additive, and recessive modeling was performed
in response to therapy and ADRB1 polymorphisms to
determine the odds ratio (OR) and adjusted for age and
gender. Statistical significance was defined as a 2-sided p 
0.05. Statistical analysis was performed with PLINK and
PASW Statistics software (version 18.0.0, IBM, Armonk,
New York).
Haplotypes were estimated using the 2 SNPs by applying
standard expectation–maximization algorithms and measured
for degree of linkage disequilibrium (LD) represented by r2.
or drug–group distribution analysis, we considered atenolol,
arvedilol, metoprolol, and propranolol from -blockers (BBs),
iltiazem and verapamil from calcium channel blockers
CCBs), and digoxin. Given the various types of BBs that can
e used in the clinical setting, for drug–haplotype distribution
mong responders, we considered the most commonly pre-
cribed BBs and CCBs in our study, defined a priori for the
nal analysis. All drug doses are expressed as milligrams per
ay representing the final total mean medication dose required
or ventricular rate control of AF.
esults
total of 587 patients were enrolled over a 36-month
eriod. Forty-four subjects were non-Caucasians (37 Afri-
an Americans and 7 Asians) and hence excluded from the
nalysis.
atient demographics and clinical characteristics. The
linical characteristics of the study population are listed in
able 1. Our study population included 543 Caucasian
atients; 344 men and 199 women. The mean age of the
ohort was 61.8  14 years. Two hundred ninety-five
atients (54%) met the AFFIRM criteria and were classified
Study Cohort DemographicsTable 1 Study Cohort Demographics
Responders
(n  295)
Nonresponders
(n  248)
Age, yrs 61 14 62 14
Heart rate, beats/min 76.4 20.2 70.6 15.3*
Male 194 (65%) 150 (60%)
Comorbidities
Hypertension 129 (44%) 115 (46%)
Coronary artery disease 56 (19%) 39 (16%)
Congestive heart failure 32 (11%) 29 (12%)
Diabetes mellitus 35 (12%) 31 (12%)
Hyperthyroid 7 (2%) 3 (1%)
Smoking 17 (6%) 3 (1%)*
Echocardiographic variables
Left atrial size, mm 42.6 8.5 42.4 8.9
Left ventricular ejection fraction, % 53.5 12.2 54.4 11.8Values are mean  SD or n (%). *p  0.05 vs. responders.s responders. The final drug prescription distribution was
67 in responders and 595 (310 AADs and 285 rate-control
rugs) in nonresponders. In responders, drug class distribu-
ion was 61%, 31%, and 8% for BBs, CCBs, and digoxin,
espectively, compared with 43%, 28%, and 29%, respec-
ively, in nonresponders. Thirty-one patients (12.5%) in the
onresponder group underwent AV node ablation and
acemaker implantation for treatment of AF, and  51% of
onresponders required concurrent administration of an
AD (amiodarone: 35%, sotalol: 33%, propafenone: 15%,
ecainide: 15%, and procainamide: 2%). In responders,
ombination treatment was required with BBs and CCBs in
0% of cases, CCBs and digoxin in 25% of cases, BBs and
igoxin in 13% of cases compared with BBs and CCBs in
5% of cases, BBs and digoxin in 67% of cases, respectively,
f nonresponders. Only 35 (12%) patients among respond-
rs were adequately rate controlled with BBs alone versus 17
7%) patients from nonresponders who were also on at least
concurrent AAD. This precluded us from undertaking a
ubanalysis looking at the modulatory effect of ADRB1
olymorphism on patients taking BBs only.
In our cohort, we observed a similar trend in HR as
reviously reported, with homozygotes for the Arg389 allele
aving the highest HR (75  19 beats/min), followed by
rg389Gly (74  20 beats/min) and homozygotes for
ly389 variant (71  15 beats/min).
1-AR genotypes. Our genotype call rate was 498 of 543
(92%) at position 49 and 513 of 543 (95%) at position 389.
The genotype frequencies of ADRB1 polymorphisms in our
cohort did not deviate significantly from Hardy-Weinberg
equilibrium. Arg389Gly minor allele frequency: 0.28 (re-
sponders) versus 0.26 (nonresponders), p  0.5, Ser49Gly
inor allele frequency: 0.14 (responders) versus 0.15 (non-
esponders), p 0.5. The haplotype frequency in our cohort
as Arg389Arg-Ser49Ser (37%), Arg389Arg-Ser49Gly
15%), Arg389Arg-Gly49Gly (2%), Arg389Gly-Ser49Ser
30%), Arg389Gly-Ser49Gly (10%), Arg389Gly-Gly49Gly
(0%), Gly389Gly-Ser49Ser (6%), Gly389Gly-Ser49Gly (0%),
nd Gly389Gly-Gly49Gly (0%). We observed weak LD
etween the 2 SNP, with r2  0.045. The clinical charac-
teristics of responders and nonresponders by genotype
Ser49Ser versus Gly49 carriers and Arg389Arg versus Gly389
carriers are listed in Tables 2 and 3.
Overall, 13% of our study population had a positive
family history of AF. Analysis did not reveal any correlation
between family history and polymorphism at either position
49 (Ser49Ser [13%] vs. Gly49 carriers [16%], chi-square p
0.315) or position 389 (Arg389Arg [15%] vs. Gly389 carriers
[11%], chi-square p  0.214).
Response to rate-control therapy. Two hundred ninety-
five (54%) patients responded adequately to rate-control
therapy. Carriers of the Gly variant at 389 were more likely
to respond favorably to rate-control therapy; 60% respond-
ers in carriers of minor allele group versus 51% in Arg389Arg
genotype, chi-square p  0.04. Polymorphism at position
49 did not influence response to rate-control therapy; 52%
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Ser49Ser genotype; chi-square p  0.45 (Fig. 1). In regres-
ion analysis, multiple clinical variables (age, HTN, gender)
ailed to significantly predict adequate response to rate-
ontrol therapy. By contrast, dominant model (identical
ffect is expected in heterozygous and homozygous variant
arriers), showed a significant association of adequate rate
ontrol with the Gly389 variant allele (OR: 1.44, 95%
onfidence interval [CI]: 1.01 to 2.04, p  0.05). This
ssociation persisted after correction for age and gender
OR: 1.42, 95% CI: 1.00 to 2.03, p  0.05). Polymorphism
t position 49 was not significantly associated with adequate
ate control under all 3 genetic models (Table 4).
aplotype-response association analysis also confirmed that
he Gly variant at position 389 significantly favors adequate
ate-control therapy. Since Ser49Ser did not influence out-
Clinical Characteristics of Responders and NonresTable 2 Clinical Characteristics of Responder
Responders (n
Ser49Ser
(n  200)
Age, yrs 62 13
Heart rate, beats/min 75.6 20
Male 70
Comorbidities
Hypertension 56
Coronary artery disease 23
Congestive heart failure 15
Diabetes mellitus 12
Hyperthyroid 2
Smoking 6
Echocardiographic variables
Left atrial size, mm 42 9
LVEF 53.2 12.4
Values are mean  SD or %. *p  0.05.
LVEF  left ventricular ejection fraction.
Clinical Characteristics of Responders and NonresTable 3 Clinical Characteristics of Responder
Responders (n
Arg389Arg
(n  137)
G
Age, yrs 60 14
Heart rate, beats/min 77.0 20.5
Male 63
Comorbidities
Hypertension 52
Coronary artery disease 22
Congestive heart failure 11
Diabetes mellitus 15
Hyperthyroid 3
Smoking 2
Echocardiographic variables
Left atrial size, mm 43 9.7
LVEF 55 10.7Values are mean  SD or %. *p  0.05.
LVEF  left ventricular ejection fraction.ome of therapy as a haplotype with Arg389Arg, we think
he effect observed with Arg389Gly-Ser49Ser haplotype is
rimarily driven by the Gly389 variant (Fig. 2).
Among responders, patients with Arg389Arg-Ser49Ser
aplotype required the highest doses of BBs and CCBs to
chieve adequate rate control than patients with Arg389Gly-
er49Ser haplotype who required the lowest doses; atenolol:
2 mg versus 68 mg; carvedilol: 44 mg versus 20 mg;
etoprolol: 80 mg versus 72 mg; diltiazem: 212 mg versus
80 mg, and verapamil: 276 mg versus 200 mg, respectively
p  0.01 for all comparisons). It is noteworthy that there
as no statistical difference in the number of medications
rescribed among these haplotypes (as shown in Table 5),
uggesting the difference in doses to be truly related to
enotypes. Similarly, in categorizing drug prescription dis-
ribution by genotype at position 389 (137 [Arg389Arg] vs.
ers by Genotype at Position 49Nonresponders by Genotype at Position 49
0) Nonresponders (n  228)
Carriers
70)
Ser49Ser
(n  162)
Gly49 Carriers
(n  66)
 16 62 14 61 14
 20 70.6 15.6 70.8 15.5
57 62 58
53 52 49
20 18 18
9 13 15
21 13 16
2 1 0
3 1 1
 6.3* 42.2 9 42.5 9
 12 53.6 11 54.7 13
ers by Genotype at Position 389Nonresponders by Genotype at Position 389
2) Nonresponders (n  231)
Carriers
145)
Arg389Arg
(n  133)
Gly389 Carriers
(n  98)
 14 62 14 63 14
 21 72.4 15.4 68 15.2*
9 62 61
7 56 50
5 18 17
5 12 15
4 14 14
2 0 1
9* 0 0
 7.3 42.7 9.3 42.8 8.4
 13 54.3 12.2 54.7 9.8ponds and
 27
Gly49
(n 
60
79
44.6
54ponds and
 28
ly389
(n 
62
76
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December 27, 2011/January 3, 2012:49–56 Genetic Predictors of AF Rate-Control Therapy129 [Arg389Gly]), there was no statistical difference in the
number of drugs prescribed for each genotype group:
atenolol (22 [Arg389Arg] vs. 26 [Arg389Gly]); carvedilol
(13 [Arg389Arg] vs. 11 [Arg389Gly]); metoprolol (47
[Arg389Arg] vs. 46 [Arg389Gly]); digoxin (13 [Arg389Arg]
vs. 8 [Arg389Gly]); diltiazem (41 [Arg389Arg] vs. 45
[Arg389Gly]); and verapamil (14 [Arg389Arg] vs. 13
[Arg389Gly]) (p  0.05 for all comparisons).
Discussion
Our study is the first to our knowledge to demonstrate that
a common ADRB1 polymorphism Arg389Gly predicts a
avorable response to rate-control therapy in AF patients.
ly389 variant is present in 24% to 46% of humans across
Figure 1 Response to Rate-Control Therapy
Based on 1-AR Genotype
Bar graph depicting percentage of patients with atrial fibrillation (AF) harboring
2 common 1-adrenergic receptor polymorphisms, Ser49Gly and Arg389Gly,
who responded to rate-control therapy.
Logistic Regression of 2 Common 1-AR PolymAr 389Gly and Ser49Gly, and Response to RateTable 4 Logistic Regression of 2 Common Arg389Gly and Ser49Gly, and Resp
Model OR
Arg389Gly
Dominant CC  270, CG/GG  243 1.44
Additive CC  270, CG  129, GG  40 1.11
Recessive CC/CG  473, GG  40 0.51
Ser49Gly
Dominant AA  362, AT/TT  136 0.86
Additive AA  362, AT  63, TT  10 0.93
Recessive AA/AT  488, TT  10 2.00
Rate-control therapy was with -blockers, calcium-channel blockers, o
AA  Ser49Ser; AT/TT  Gly49 carriers; CC  Arg389Arg; CG/GG  Gly38
odds ratio.ifferent races, making our finding especially significant
ith respect to its clinical implications.
AV node physiology and distribution of ion channels,
specially L-type calcium channels, and ADRB1 alters
reatly from ventricular myocytes, which have been the
rimary source of in vitro functional studies of ADRB1. The
ctivity of L-type calcium channels in the AV nodal N cells
etermines the velocity of depolarization during the up-
troke of an action potential. These calcium channels are
urther augmented by catecholamine activation of ADRB1-
ediated channel phosphorylation through enhanced
AMP production (15,16). This mechanism explains why
he majority of patients with AF required concurrent
ms,trol TherapyPolymorphisms,
to Rate-Control Therapy
justed Adjusted*
CI p Value OR 95% CI p Value
.04 0.043* 1.42 1.00–2.02 0.05
.46 0.45 1.08 0.82–1.43 0.58
.00 0.05 0.48 0.25–0.93 0.03†
.27 0.45 0.94 0.63–1.41 0.76
.33 0.69 1.00 0.69–1.45 0.98
.81 0.32 2.00 0.50–7.94 0.32
in. *Adjusted for age and gender; †p  0.05.
Figure 2 Response to Rate-Control Therapy
Based on 1-AR Haplotype
Bar graph depicting percentage of patients with atrial fibrillation with haplotype
distribution and therapy outcome (*p  0.001). 1AR  1-adrenergic
receptor.orphis-Con1-AR
onse
Unad
95%
1.01–2
0.85–1
0.27–1
0.58–1
0.65–1
0.51–7
r digox
9 carriers; CG and AT  heterozygous; CI  confidence interval; OR 
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Genetic Predictors of AF Rate-Control Therapy December 27, 2011/January 3, 2012:49–56administration of BBs and CCBs for a synergistic effect for
rate control.
Gly389 is a loss-of-function variant; consequently, for the
same adrenergic stimulation, it produces reduced levels of
adenyl cyclase and hence attenuates the -adrenergic cas-
ade and its downstream effect in cardiomyocytes, reducing
ain in excitation-contraction coupling with catecholamin-
rgic surge (17). Furthermore, the predicted effect of the
rg389Gly variant would be to slow conduction and increase
Drug Prescription Distribution AmongResponders by Haplotype Arg389Arg-Ser49Ser(n  85) and Arg389Gly-Ser4 Ser (n  97)
Table 5
Drug Prescription Distribution Among
Responders by Haplotype Arg389Arg-Ser49Ser
(n  85) and Arg389Gly-Ser49Ser (n  97)
Medication
Responders (n  291)
Arg389Arg-Ser49Ser
(n  141)
Arg389Gly-Ser49Ser
(n  150)
Atenolol 25 24
Carvedilol 13 14
Metoprolol 44 49
Propranolol 3 0
Diltiazem 34 42
Verapamil 15 11
Digoxin 7 10
Shown are the total number of rate-control prescriptions.
Figure 3 Synergism Between 1-AR Polymorphism and Rate-Co
Schematic representation of the 1-adrenergic receptor (1-AR) polymorphism in t
and calcium channel blockers (CCBs). AC  adenyl cyclase; CaCn  calcium chanefractoriness in the AV node, thus reducing ventricular
ates in AF. Mechanistically, the effect of BBs and CCBs on
he conduction and refractoriness of the AV node will be
ynergistic with that of the Arg389Gly variant, which could
ossibly explain our findings (Fig. 3).
In our study, only 13% of patients required concurrent use
f digoxin with BBs. Digoxin slows AV node conduction
nd prolongs the effective refractory period. These actions
n the AV node are secondary to its effect on increasing
agal tone and release of acetylcholine from the parasym-
athetic nerve terminals in the AV node, However, there
re no studies to our knowledge that have looked at 1-AR
olymorphisms and digoxin in patients with AF or heart
ailure.
Studies have reported weak to strong LD between these
ADRB1 SNPs, making it difficult to relate ex vivo with in
ivo findings (18,19). In our cohort, we observed weak LD
etween the 2 SNPs. Furthermore, our results show that AF
atients who harbored the functional variant Arg389Gly had
significantly favorable response to rate-control therapy.
aken together, this suggests that of the 2 SNPs, Arg389Gly
rives outcome to rate-control therapy in patients with AF.
Clinical studies examining the influence of ADRB1 poly-
orphism on BB response in patients with CHF have met
l Therapy in AF
oventricular node and augmentation of the effects of -blockers (BBs)
s  G protein; PKA  protein kinase A.ntro
he atri
nel; G
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December 27, 2011/January 3, 2012:49–56 Genetic Predictors of AF Rate-Control Therapywith variable results. Mialet Perez et al. (20) found substan-
tial improvement in left ventricular ejection fraction with a
standardized-dose regimen of carvedilol in Arg389 homozy-
gous patients. However, in a study by Chen et al. (21),
similar improvement was observed in Gly389 homozygous
patients. Likewise, in CHF patients, Arg389 homozygotes,
ut not Gly389 carriers, treated with bucindolol had a
ignificant reduction in mortality and morbidity when
ompared with placebo (22). In a substudy of MERIT-HF
Metoprolol CR/XL Randomized Intervention Trial in
ongestive Heart Failure) in which patients were treated
ith metoprolol, no significant difference in all-cause mor-
ality or hospitalization was observed in patients homozy-
ous for either the Arg389 or Gly389 variants (23). The
llelic distribution of ADRB1 polymorphism at codon 49
as found to be associated with long-term survival of
atients with chronic HF: 46% mortality rate in Ser49
arriers versus 23% in carriers of the Gly49 variant (24).
owever, other studies have not been able to reproduce
hese findings (25). In our study, Ser49Gly polymorphism
id not influence the outcome of rate-control therapy in
atients with AF.
Recent randomized trials of rhythm versus rate-control
trategies of treatment in patients with AF suggest that rate
ontrol is a viable first-line strategy in many patients (2,26).
t can improve symptoms, exercise capacity, and cardiac
unction, however, identification of patients likely to re-
pond to this approach is challenging (26–28). Currently,
here is no widely accepted method of predicting who will
espond adequately to rate-control therapy and who will
equire escalation and/or change in therapy. Certainly, there
re no studies that have assessed genetic predictors of
ate-control therapy in AF patients. Rate control of AF can
e challenging, and often drugs have to be changed and
ombination therapy is needed to achieve adequate rate
ontrol (13).
Our data suggest a potential role of screening for a
ommon ADRB1 polymorphism Arg389Gly in AF pa-
ients who will favorably respond to rate-control therapy.
urthermore, requirement of higher doses of BBs and
CBs for rate control in AF rate leading to clinical
dverse effects is also commonly encountered. In our
tudy population, metoprolol among BBs and diltiazem
mong CCBs were the most commonly prescribed rate-
ontrol agents for the treatment of AF, and subjects with
he Arg389Arg genotype consistently required higher
oses, which may increase the possibility of potential
dverse effects. This also suggests a role for genotyping
atients for common variants in ADRB1 to predict
equirement for higher doses of rate-control medications.
owever, further studies are needed to validate our
nding before clinical use is recommended.
tudy limitations. To our knowledge, this is the first and
he largest study to date looking at the effects of ADRB1
olymorphism on rate-control therapy in patients with AF.
owever, there are certain limitations to consider. First, weannot correct for daily alterations in HR (conditions such
s exercise, stress, sleep) that are driven by catecholamine-
ediated activation of AR, but considering that this vari-
bility exists in all our patients, the effect would be spread
venly and would not be considered confounding. Second,
y selecting the AFFIRM criteria for adequate rate control,
e were able to monitor alterations in HRs of our patients
ith either a 6-min walk test or 24-h Holter monitoring.
hird, the study population is derived from patients pre-
enting to a large, tertiary referral center and may not
epresent the population with AF in other settings; none-
heless, the frequency of ADRB1 alleles identified in this
opulation corresponds to previously published frequencies.
inally, it is uncertain whether the current study’s findings
an be generalized to non-Caucasian populations due to
onsiderable differences in minor allele frequencies and
xclusion from the analysis due to small sample size (n 
4) (4).
There was no standard protocol for titration of rate-
ontrol medications or changes to a rhythm-control strat-
gy. The management of study patients was left at the
iscretion of the treating physicians who were blinded to the
tudy protocol and genotype data. Although this lack of
tandardization inevitably introduces heterogeneity to the
ndpoints considered, it reflects a “real world” practice
nvironment and increases the applicability of these results
o clinical daily practice. Currently, there are several types of
Bs that can be used for rate-control therapy in patients
ith AF. In our study, we had defined a priori to consider
he most commonly prescribed BBs and CCBs in the final
rug–haplotype analysis, thus providing a detailed and
ell-powered analysis.
onclusions
e have shown that a common ADRB1 polymorphism
rg389Gly predicts favorable response to rate-control ther-
py in AF patients. Being a loss-of-function variant that
ecreases conduction and increases refractoriness in the AV
ode, it is physiologically sound to consider that it works
ynergistically with BBs and CCBs. Confirmatory studies
re needed before clinical use of our data is recommended.
hese findings represent a step forward in the development
f a long-term strategy of selecting treatment options in AF
ased on genotypes.
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